PATENT CLAIM ANALYSIS

Application Number: 15910525
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["424", "186100"]

Abstract:
Modified viruses and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including cancer, and as anti-tumor and/or antiangiogenic agents. The viruses also can be used in diagnostic methods.

Claim (Index 1):
A method of treatment of cancer, comprising administering a recombinant vaccinia virus to a subject for the treatment of a tumor or metastasis, wherein:\n the recombinant vaccinia virus encodes a diagnostic or therapeutic protein selected from among a ferritin, click beetle green 99 luciferase-monomeric red fluorescent protein fusion (CBG99-mRFP1), plasminogen kringle 5 domain, a soluble IL-6 receptor-IL-6 fusion protein (sIL-6R/IL-6), interleukin-24 (IL-24), a truncated human tissue factor protein fused to an RGD peptide (tTF-RGD) and an anti-VEGF single chain antibody or fragment thereof; and the nucleic acid encoding the diagnostic or therapeutic protein is inserted into a non-essential locus in the virus.

Metadata:
- Claim Count in Document: 41.0
- Percentile: 90.0
- Lexical Diversity: 1.63889
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14638604', '13136519', '11975090', '12080766', '12660314']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7037622494657251
- 35 USC 102 Novelty (BERT): 0.6191509850239074
- Combined Prediction Score: 0.6953011230215433
- Mean Citation Score: 511.316062
- Max Citation Score: 563.9477
- Similarity Product: 517.1344921859146

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test